SecBot SecBot
SECBOTREPLAY Home › Report › TOVX

TOVX · Theriva Biologics received regulatory authorization from the Spanish…

Theriva Biologics, Inc. · 8-K filed Jul 7, 2026 at 08:10 ET

At the news

BULLISHIMPACT 5/10

8-K filed Jul 7, 2026 at 08:10 ET

Theriva Biologics received regulatory authorization from the Spanish AEMPS to initiate the VIRAGE2 Phase 2a clinical trial, a 6-patient proof-of-concept study evaluating more frequent dosing (at least 3 doses) of oncolytic adenovirus VCN-01 in first-line metastatic pancreatic cancer. The trial builds on prior VIRAGE Phase 2b data where 2-dose VCN-01 showed significantly improved overall survival, progression-free survival, and duration of response versus 1-dose or chemotherapy alone. This is an early exploratory step toward a potential pivotal Phase 3 trial, but no financial data, guidance, or near-term revenue catalyst is provided.

  • Spanish AEMPS authorized initiation of VIRAGE2 Phase 2a trial for VCN-01 in first-line metastatic pancreatic cancer
  • VIRAGE2 is a 6-patient, single-arm, open-label, proof-of-concept trial evaluating at least 3 doses of VCN-01 given 2 months apart with gemcitabine/nab-paclitaxel
  • Prior VIRAGE Phase 2b (112 patients) showed 2-dose VCN-01 significantly improved overall survival, progression-free survival, and duration of response vs 1-dose or chemotherapy alone
  • EMA and FDA recognized improved survival with 2-dose VCN-01 and suggested more frequent dosing could improve outcomes

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access